Drug Development


  • Isoquercetin patented formulation (Kinisoquin™)
  • Isoquercetin prevents platelet activation and initiation of the thrombotic cascade.
  • Over 20’000 publications referencing Isoquercetin and Quercetin in multiple indications.
  • Safety profile of Kinisoquin™ (our main investigational drug) is well established. It has been shown not to increase bleeding risk – a significant advantage over Heparins and Direct Oral Anticoagulants

" While thrombosis is a major problem affecting cancer patients, the primary concern with currently available anticoagulants is the increased risk of hemorrhage. In randomized studies, the directoral anticoagulants effectively reduced the incidence of thrombosis but at a cost of doubling the rate of major hemorrhage. Developing an effective and safe antithrombotic agent would greatly improve adoption of primary prevention strategies in the cancer community. "

— Jeffrey Zwicker, MD Professor of Medicine
Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK), New York, USA

Lead indication: VTE prevention in cancer

  • Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality among patients with cancer.
  • Besides increased risk of VTE, advanced cancer patients have a significantly increased bleeding risk.
  • Major bleeds are a side effect of the anticoagulants in use today which include LMWH and DOACS which cause bruising and bleeding with other side effects.
  • As a result, Venous thromboembolism (VTE) prevention remains limited for advanced cancer patients, despite these patients being at a high risk of VTE.
  • Currently, anticoagulant use is not recommended for prophylactic use in cancer patients due to significantly increased bleeding risk.
  • Kinisoquin™ is expected to prevent VTE effectively without increased risk of bleeding in advanced cancer patients.

Pipeline indications

  • Reduction of tumor metastasis
  • Treatment of Ovarian Cancer and other solid tumors
  • Treatment of Sickle Cell Disease (SCD)
  • Treatment of Amyotrophic Lateral Sclerosis (ALS)
  • Test for Thrombosis Risk
  • Other cancers and diseases with high risk of thrombosis

NIH discussion about Kinisoquin™and sickle cell disease